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Abstract
Background: Prostate-specific membrane antigen (PSMA) is a cell surface glycoprotein with a large extracellular domain with 
overexpression of the prostatic tumour cells. Several small molecules of PSMA ligands of inhibitors binding to the active site 
of PSMA were developed. [99mTc]Tc-PSMA-T4 is a new radiopharmaceutical (Polatom) for imaging loco-regional metastases 
and/or local relapse in patients with prostate cancer.
The purpose of this work was to evaluate the clinical application of SPECT-CT imaging with [99mTc]Tc-PSMA-T4 in patients with 
recurrent prostate cancer.
Material and methods: Thirty-six patients with prostate cancer, aged 60–80 years with biochemical relapse of PSA (ranged 
from 0.1 to 73 ng/mL) were included. Three patients were studied after tru-cut biopsy, hormonal and cytoreductive radiotherapy 
and 33 patients out of 36 — after radical treatment (total prostatectomy or definitive radiotherapy of the tumour). All of them 
underwent whole-body imaging examinations with subsequent target SPECT-CT studies of the pelvis, abdomen and/or chest, 
1–3 hrs post i.v. administration of [99mTc]Tc-PSMA-T4. The average activity dose was 6.3 MBq/kg in a man of 70 kg. A Dual-head 
SPECT-CT gamma camera with a low dose CT scan (Symbia T2, Siemens) was used. The images were interpreted based on 
all other clinical and radiological data. Follow-up could be conducted in 11/36 patients during that period.
Results: Normal biodistribution of the radiopharmaceutical with high activity background was observed in the liver, spleen, 
kidneys, lacrimal and salivary glands, bowels and urinary bladder. Positive imaging for local relapse in the prostate bad was 
imaged in 21 patients, lymph node metastases — in 16 cases, bone lesions — in 10 cases, pulmonary metastases – in 2 cases, 
hepatic lesions were visualised in one of them and in another — adrenal suprarenal metastasis with intensive tracer uptake 
significant for overexpression of PSMA. There was a suspicion for local recurrences in 4 patients with negative MRT studies 
who were followed up. In 3 cases, previously treated bone metastases were partially negative without tracer uptake, only some 
progressive bone lesions were positive. Five patients were with negative results. Sensitivity was 84.37% (27/32), specificity — 
100% (4/4) and accuracy — 86.11% (31/36).
Conclusions: In conclusion SPECT-CT imaging with [99mTc]Tc-PSMA-T4 could be applied in patients with prostate cancer for 
the diagnosis of recurrent disease to determine personalized treatment for each patient. Specific uptake of this tracer, depicted 
by SPECT-CT images has clinical importance of identifying and assessing PSMA expression before consideration of Radio 
Ligand Therapy (RLT) with [177Lu]Lu-PSMA. SPECT-CT imaging with [99mTc]PSMA is promising and reliable nuclear medicine 
approach to monitoring therapeutic effect after treatment and for restaging of the disease.
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Introduction
Prostate cancer is the most common malignancy in men in 
Europe. According to forecast statistics for 2018, the number 
diagnosed with this disease is 450,000 men or 20% of all cases of 
malignancies in them [1]. This disease is socially significant both in 
Bulgaria and in the countries of the European Union. The incidence 
in 2018 (standardized indicator per 100,000 men) varies from 80.2 
in Romania to 265.2 in Ireland. In Bulgaria, the incidence is 136.4, 
14% lower than the European Union average, but with a tendency 
to increase. Mortality in 2018 varies from 22.7 in Italy to 73.9 in 
Estonia. In Bulgaria, the mortality rate is 40.1 and is 7% higher than 
the average for the European Union, with a tendency to increase, 
and the survival rate is the lowest among the European — 68% 
[1, 2]. Interpretation of these factual data points out that modern 
diagnostic and therapeutic methods have not yet shown their im-
pact on epidemiological indicators in Bulgaria as well as in some 
other European countries. The reasons for this are complex and 
diverse for different countries.
One of the important clinical problems is the early detection 
and visualization of recurrences after prostatectomy, radiotherapy 
or other definitive local treatment, with PSA values  above 0.2 ng/mL. 
Contrast-enhanced magnetic resonance imaging (MRI) and com-
puted tomography (CT) scans are most commonly used, but they 
are not always of sufficient sensitivity and specificity, especially at 
low tumour marker values [3, 4].
With the introduction of molecular high sensitive imaging 
after administration of radiolabelled prostate-specific mem-
brane antigen (PSMA), it has become possible to obtain early 
functional information for disease development and recurrence 
detection, which is more accurate than that of CT or MRI in many 
cases [5, 6]. 
Prostate-specific membrane antigen (PSMA) is a cell surface 
glycoprotein with a large extracellular domain with overexpression 
of the prostatic tumour cells. This membrane antigen is known 
as glutamate carboxypeptidase II (GCP II), a membrane-bound 
binuclear zinc metallopeptidase, which is available in low concen-
trations in normal kidney, intestinal tissue and salivary glands [7, 8]. 
PSMA overexpression is observed also in endothelial cells of tumour 
neovasculature of non-prostatic solid tumours and benign lesions: 
colon, gastric, breast, thyroid, ovary; Paget Disease, probably stim-
ulated by secreted angiogenic factors. Upon ligand binding, PSMA 
is internalized via endocytosis in the tumour cell [7, 8].
In recent years in the clinical practice, a new concept was in-
troduced for specific diagnosis and targeted effective radionuclide 
treatment of metastatic prostate cancer (PC) after administration 
of a target PSMA molecule, labelled with various radionuclides, on 
the principles of theranostics [9, 10].
The degree of intensity of PSMA overexpression epithelial 
cells in PC is proportional to the degree of malignant cell dedif-
ferentiation and metastatic spread [7, 8]. The field of radiophar-
macy and radiochemistry over the last decade is focused on the 
development of small ligand molecules or binding inhibitors with 
the active PSMA core, which are characterized by high specificity, 
good permeability in solid tumours, optimal pharmacokinetics in 
normal tissues, easily labelled and synthesized, no host-immune 
response in the recipient [7, 8].
Such PSMA ligands can be labelled with different radionuclides, 
respectively with 68Ga, 18F, 99mTc, 123/124I (emitting positron or gam-
ma emission) for diagnostic purposes or with 177Lu, 131I, 90Y, 225Ac 
(emitting beta or alpha emissions) to conduct target radioligand 
therapy. The most used diagnostic radiopharmaceutical is the 68Ga 
PSMA-11 inhibitor [6, 8, 10]. 
After intravenous application of gamma-emitting radiophar-
maceutical [99mTc]PSMA or positron-emitting [68Ga]PSMA, positive 
scans were significant for the presence of PSMA overexpression, 
this information is important for the assessment of malignant le-
sions and disease extension [5, 6].
Several small molecules of PSMA ligands or inhibitors were 
developed. One such small ligand binding to the active site of 
PSMA, namely PSMA-T4 (Glu-CO-Lys-L-Trp-4-Amc-HYNIC) and the 
kit formulation for its radiolabelling with technetium-99m resulting 
in the [99mTc]Tc-PSMA-T4radiopharmaceutical were developed at 
Radioisotope Centre Polatom, National Centre for Nuclear Research 
in Otwock, Poland.
The purpose of this study was to evaluate the clinical role of 
[99mTc]Tc-PSMA-T4 for imaging of local relapse and/or loco-regional 
and distant metastases in patients with recurrent prostate cancer 
and biochemical disease progression.
Material and methods
Patients
This was a prospective study conducted in the period January 
2019 — January 2020 after preliminary approval of this scientific 
project on the Local Ethics Committee. A cohort of 36 patients, aged 
60–80 years/average of 69.44 years/ with prostate cancer was ex-
amined after obtaining written informed consent. Three patients un-
derwent tru-cut biopsy, hormonal and cytoreductive radiotherapy; 
33 patients out of 36 received radical treatment of primary cancer 
(total prostatectomy or definitive radiotherapy of the tumour). There 
was laboratory data on biochemical disease progression — serum 
value elevation  of the tumour marker PSA and its doubling within 
6 months. The average serum PSA level before SPECT-CT imaging 
was 6.73 ng/mL (ranged from 0.1 to 73 ng/mL) (Tab. 1).
All of the patients underwent whole-body imaging examina-
tions with target SPECT-CT studies 1–3 hrs post intravenous ad-
ministration of [99mTc]Tc-PSMA-T4. 
Radiolabelling
PSMA-T4 (Glu-CO-Lys-L-Trp-4-Amc-HYNIC, 23 mcg) in the form 
of a dry kit for radiolabelling with technetium-99m has been obtained 
from National Centre for Nuclear Research (Polatom, Poland) and 
was radiolabelled with technetium-99m according to the procedure: 
to the kit vial, 1 to 2.5 mL of sodium pertechnetate solution (eluate 
from the 99Mo/99mTc generator) with radioactivity in the range from 
370 to 1500 MBq was added. The content of the vial was gently 
mixed for 30 seconds to allow complete dissolution, then heated 
in the boiling water bath for 15 min and afterwards cooled down at 
room temperature for 10 min. Radiolabelling yield was more than 
95% as assessed by instant thin-layer chromatography (ITLC). 
The complex [99mTc]Tc-PSMA-T4 was stable for not less than 4 h. 
The average activity dose injected intravenously was 6.3MBq/kg 
in a man of 70 kg.
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Table 1. Clinical and pathological characteristics of the 36 patients with biochemical recurrence of prostate cancer
Pt No/Age TNM Stage Gleason Score PSA at SPECT-CT Image Primary Therapy
1/67 years pT3bpN1M0 7 (4 + 3) 0.271 ng/mL RP, RT, ADT
2/73 years T3N0M0 7 (4 + 3) 12 ng/mL RT, ADT
3/71 years T3N0M0 8 (4 + 4) 73 ng/mL RT, ADT, Chemotherapy
4/68 years pT2pN0M0 7 (4 + 3) 0.30 ng/mL RP
5/67 years T3N1M0 9 (5 + 4) 9.68 ng/mL RT,ADT
6/ 64 years T3bN1M0 9 (5 + 4) 2.15 ng/mL Cytoreductive RT, ADT, 
Chemotherapy
7/63 years pT2pN0M0 7 (3 + 4) 0.12 ng/mL RP
8/65 years pT3pN0M0 6 (3 + 3) 0.36 ng/mL RP
9/ 70 years pT2pN0M0 7 (3 + 4) 0.24 ng/mL RP, RT
10/64 years pT2cpN0M1 7 (4 + 3) 0.82 ng/mL RP, ADT
11/70 years pT2pN0M0 7 (4 + 3) 0.69 ng/mL RP,ADT
12/79 years T3N0M0 10 (5 + 5) 10.87 ng/mL RT, ADT, Chemotherapy
13/60 years pT2pN0M0 5 (3 + 2) 0.50 ng/mL RP
14/64 years T3aN0M0 7 (4 + 3) 0.16 ng/mL RP, ADT
15/74years pT3bpN1M0 9 (5 + 4) 0.35 ng/mL RP, RT, ADT, Chemotherapy
16/75years pT2cpN0M0 7 (4 + 3) 0.57 ng/mL RP, RT, ADT
17/75years pT2cpN0M0 7 (4 + 3) 0.36 ng/mL RP
18/70years T3bN0M1 7 (3 + 4) 58 ng/mL RT, ADT
19/62years T3bN1M1 8 (4 + 4) 0.66 ng/mL Cytoreductive RT, ADP
20/68years T2NxM1 7 (4 + 3) 0.41 ng/mL RT, ADT
21/63years T3aN0M0 7 (4 + 3) 1.78 ng/mL RT, ADT
22/77years pT2pN0M0 7 (3 + 4) 1.5 ng/mL RP, ADT
23/69years T2NxM0 7 (4 + 3) 7.3 ng/mL RT, ADT
24/79years pT2pN0M0 6 (3 + 3) 1.42 ng/mL RP, RT, ADT
25/64years T4N1M1a 8 (4 + 4) 14 ng/mL RT, ADT
26/77years T3aN0M0 7 (3 + 4) 0.8 ng/mL  RT
27/66years T2N0M0 8 (4 + 4) 1.88 ng/mL RT
28/69years pT2pN0M0 7 (4 + 3) 0.25 ng/mL RP, RT
29/60years pT2pN0M0 5 (3 + 2) 0.77 ng/mL RP, ADT
30/78years T1cN1M1 8 (4 + 4) 27 ng/mL RT, ADP
31/69years pT2N0M0 5 (3 + 2) 1.6 ng/mL RP, ADP
32/70years pT2N0M0 7 (4 + 3) 0.23 ng/mL RP, RT
33/73years T4N1M0 9 (4 + 5) 0.30 ng/mL Cytoreductive RT, ADP
34/80years T2N0M0 7 (4 + 3) 5.90 ng/mL RT, ADP
35/70years pT3bpN0M0 8 (4 + 4) 1.72 ng/mL RP, ADP
36/71years pT2cpN0M0 8 (5 + 3) 0.47 ng/mL RT, ADP
RP — radical prostatectomy; RT — radiotherapy; ADT — androgen deprivation therapy
Imaging protocol
Whole-body imaging examinations with subsequent target 
SPECT-CT studies of the pelvis, abdomen and/or chest and were 
carried out 1–3 hrs. after tracer application. SPECT-CT gamma 
camera Symbia T2, Siemens, was used for topographic localization 
and morphological substratum of “hot” abnormal foci. Dual-head-
SPECT acquisition included 64 projections, 25 s/projection, matrix 
256 × 256. A low dose CT scan was performed in the helical mode. 
Acquisition parameters included settings at 130 kV, 30 mA; 3–5 mm 
slice thickness. 
SPECT-CT images were analysed considering any focal 
abnormal uptake of [99mTc]Tc-PSMA-T4 above the surrounding 
background level, not associated with physiological biodistri-
bution, suggestive of malignancy. The diagnostic differentiation 
between malignant and inflammatory lymph nodes is based 
not only on the intensity of tracer accumulation but also on 
the morphological structure of the nodule and the anatomical 
localization, especially if the accumulation is bilaterally sym-
metrical in the inguinal, hilar or axillary lymph nodes. The ob-
tained SPECT-CT results were compared with the data from the 
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previously conducted diagnostic imaging studies — computed 
tomography, magnetic resonance tomography, bone scintig-
raphy. The images were interpreted based on all other clinical 
and radiological data.
Follow-up SPECT-CT studies with[99mTc]Tc-PSMA-T4 were 
performed in 11/36 patients to monitor and evaluate the results of 
baseline scans and conducted treatment. 
Results
Normal biodistribution of the radiopharmaceutical with high 
activity background was observed in the liver, spleen, kidneys, 
lacrimal and salivary glands, oral and nasal mucosa, bowels and 
urinary bladder (Fig. 1).
Positive imaging for local relapse in the prostate bad was im-
aged in 21 patients, pelvic and extra pelvic lymph node metasta-
ses — in 16 cases, bone lesions — in 10 cases, visceral lesions — in 
3 cases: pulmonary metastases — in 2 cases, hepatic and adrenal 
suprarenal metastases — in one of them (Fig. 2–7). The smallest 
visualized positive lymph node was axial in size 9.2 mm (Fig. 2). 
All abnormal “hot” spots were scanned with intensive tracer uptake 
significant for PSMA overexpression.
There was a suspicion of local recurrence in the prostate bed 
in 4 patients with negative MRT imaging who were followed up after 
6 months. The presence of the pathological findings was confirmed 
by the performed control studies with [99mTc]Tc-PSMA-T4, as they 
were also positive by the computed tomography or magnetic res-
onance imaging carried out in parallel.
In 4 patients negative results were obtained for local recurrence 
of the prostate, no lymphogenic spread or hematogenous dissem-
ination of the disease was observed. In these cases, the level of 
the tumour marker PSA decreased in the control studies, for these 
reasons, the data from the imaging [99mTc]Tc-PSMA-T4 study were 
interpreted as truly negative (Fig. 4).
In 3 cases with multiple bone metastases, treated palliatively 
with radiotherapy and osteomodulators, tracer uptake was found 
only in some progressive bone lesions. There was a lack of activity 
in most osteosclerotic foci, probably due to a suppressed osteo-
blastic process after treatment (Figure 7). In one of these patients, 
the study with [99mTc]Tc-PSMA-T4was performed to exclude visceral 
and lymphogenic dissemination of the disease to plan treatment 
with Xofigo infusion (Fig. 8).
Targeted radiotherapy was performed in seven patients with 
a positive result for the development of local recurrence in the 
Figure 1. M/60yr with prostate cancer, pT2pN0M0, G2, Gl = 5 (3 + 2). Radical prostatectomy (2018). PSA = 0.5 ng/mL (01/2019). Whole-body 
scan and target [99mTc]Tc-PSMA-T4 SPECT-CT imaging showed physiological tracer biodistribution in the liver, spleen, kidneys, lacrimal and 
salivary glands, oral and nasal mucosa, bowels and urinary bladder. Intensive [99mTc]Tc-PSMA-T4 uptake was visualized in the prostatic bed 
suspicious for local recurrence, follow-up was required. There was moderate symmetrical activity in the inguinal bilateral lymph nodes, which were 
visualized with normal structure and size, with well-depicted lymphocytic sinus, interpreted as reactive lymph nodes
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Figure 2. M/64yr with prostate cancer, pT3bpN1Mo, G3, Gl = 9 (5 + 4). Cytoreductive radiotherapy (01/2018), androgen deprivation therapy, 
chemotherapy. PSA = 2.157 ng/mL (01/2019). Whole-body scan and target [99mTc]Tc-PSMA-T4 SPECT-CT imaging showed local recurrence and 
enlarged bilateral obturator lymph nodes, common iliac lymph node on the right, periaortic with diameter 9.2 mm lymph node, paraesophageal 
retrotracheal lymph node and supraclavicular lymph node metastases with intensive tracer uptake
Figure 3. M/71yr with prostate cancer T3N0M0, G3, Gl = 8 (4 + 4). Radiotherapy definitive (09/2013). Androgen deprivation therapy. 
Chemotherapy and osteomodulators. PSA = 73ng/mL (02/2019). Whole-body scan and target [99mTc]Tc-PSMA-T4 SPECT-CT imaging showed 
multiple bone metastases and enlarged retroperitoneal lymph node metastases with intensive tracer uptake
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Figure 4. M/73yr with prostate cancer, T4N1M0, G3, Gl = 9 (4 + 5). Cytoreductive radiotherapy (03/2019) and androgen deprivation therapy. 
PSA = 0.30 ng/mL (06/2019). Whole-body scan and target [99mTc]Tc-PSMA-T4 SPECT-CT imaging showed enlarged prostatic gland and perivesical 
lymph nodes with intensive tracer uptake corresponding to MRT images. Disease persistence
Figure 5. M/70yr with prostate cancer, pT2N0M0, G2, Gl = 7 (3 + 4). Radical prostatectomy (2017) and radiotherapy. PSA = 0.24 ng/mL (06/2019). 
Whole-body scan and target [99mTc]Tc-PSMA-T4 SPECT-CT imaging showed local recurrence in the prostatic bed with intensive tracer uptake. 
Disease progression
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Figure 6. M/67yr with prostate cancer, pT3bpN1M0, Gl = 7 (4 + 3). Radical prostatectomy, radiotherapy (01/2018) and androgen deprivation 
therapy. PSA = 0.27 ng/mL (01/2019). Whole-body scan and target [99mTc]Tc-PSMA-T4 SPECT-CT imaging showed enlarged mediastinal lymph 
node metastases with intensive tracer uptake
prostate bed and pelvic lymphadenopathy. SPECT-CT images were 
used for contouring the gross tumour volume (GTV) and the clinical 
tumour volume (CTV) in the radiotherapy planning (Fig. 9, 10).
Negative results were found in 5 patients. They were followed 
up after 6 months, and no pathological lesions with tracer uptake 
were visualized in the second study. In this group, a continuing 
increase in serum PSA was observed: 
 — in the first patient the value of PSA before the baseline[99mTc]
Tc-PSMA-T4 study was 0.12 ng/mL and 6 months later: 
PSA = 1.42 ng/mL; 
 — in the second patient, PSA levels were 0.23 ng/mL and 
0.84 ng/mL respectively; 
 — in the third patient, PSA levels were 0.16 ng/mL and 0.25 ng/mL 
respectively;
 — in the fourth patient, PSA levels were 0.50 ng/mL and 
0.77 ng/mL respectively;
 — in the fifth patient, PSA levels were 0.24 ng/mL and 0.47 ng/mL 
respectively.
Due to the continuing biochemical progression and negative 
scan of the [99mTc]Tc-PSMA-T4study, the results in these cases were 
interpreted as false-negative images. In all patients in this group, 
the baseline PSA was less than or equal to 0.50 ng/mL.
Sensitivity of SPECT-CT study with [99mTc]Tc-PSMA-T4 for imag-
ing of recurrent prostate cancer in 36 involved patients was 84.37% 
(27/32), specificity — 100% (4/4) and accuracy — 86.11% (31/36). 
For the clinical application of this study, the following could be 
summarized:
1. SPECT-CT imaging with [99mTc]Tc-PSMA-T4 could be applied 
in patients with prostate cancer and biochemical progression 
if PSA ≥ 0.50 ng/mL for the diagnosis of recurrent disease to 
determine personalized treatment for each patient.
2.  To follow-up of patients after complex therapy for restaging of 
the disease in cases with unclear and uncertain findings from 
other imaging methods.
3. For imaging of local recurrence and/or metastases after therapy 
to perform target radiotherapy or SRT (salvage radiation therapy). 
4. Specific uptake of this tracer, depicted by SPECT-CT imag-
es could have clinical importance of identifying and assessing 
PSMA expression before consideration of Radio Ligand Therapy 
(RLT) with [177Lu]Lu-PSMA.
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Figure 7A. M/79yr with prostate cancer, T3N0M0, G3, Gl = 10 (35 + 5). Radiotherapy (2017), androgen deprivation therapy, chemotherapy. 
PSA = 10.87 ng/mL (03/2019). Whole-body scan and target [99mTc]Tc-PSMA-T4 SPECT-CT imaging showed multiple osteosclerotic bone lesions, 
partially negative due to prior treatment; B. Bone scan performed 6 months previously with a positive result for bone metastases in the pelvis, Th12 
and left shoulder. New enlarged mediastinal lymph nodes and enlarged left adrenal gland, significant for metastases, were visualized. Disease 
progression
Discussion
The first results for clinical application of radiolabelled PSMA 
were published in 2013 [5] and this led to a qualitatively new nuclear 
medicine approach to this disease with the possibility of determining 
the optimal personalized therapy for patients [6, 10–12].
The cited sensitivity and specificity of the [68Ga]Ga-PS-
MA-11 studies are very high due to the better spatial resolution of 
the PET-CT camera [13]. Compared to them, the images obtained 
by SPECT camera are characterized by lower spatial resolution, 
which is significantly improved in the combined multimodal 
SPECT-CT devices with greatly increased quality of the obtained 
images [14].
The results received in the present prospective study of the 
clinical use of [99mTc]Tc-PSMA-T4 in recurrent prostate cancer 
are comparable to those cited in the scientific literature [13, 15]. 
In a large study of 225 patients reported by Schmidkonz et al. 
[15], it was found that the detection capabilities of prostate cancer 
with the biochemical progression of [99mTc]Tc-MIP-1404 SPECT-
CT are comparable to those of 68Ga-PSMA PET-CT at levels of 
PSA > 2 ng/mL. At lower than these values and a smaller volume 
of the tumour tissue substrate, the sensitivity of SPECT-CT stud-
ies is reduced to 54% [16]. Liu et al. [17], report that at lower PSA 
values < 0.5 ng/mL the diagnostic value of [99mTc]HYNIC-PSMA 
SPECT-CT is 48.6%.
Another study showed that [99mTc]PSMA scanning was as sen-
sitive as [68Ga]Ga-PSMA-11 in 28 prostate cancer patients in 
terms of visualization of bone and lymphogenic metastatic foci, 
with PSA levels > 2 ng/mL. SPECT-CT detection was lower when 
local recurrence was detected in the prostate bed in patients with 
evidence of biochemical progression with PSA < 0.5 ng/mL [15].
Goffin et al. [18], published data that the diagnostic value 
of SPECT-CT studies with [99mTc]Tc-MIP-1404 correlated with the 
degree of differentiation of the primary tumour — Gleason score. 
In patients at intermediate risk and high-risk disease with Gl ≥ 7 
(3 + 4) detection rate reached 94% (86% for MRT); for visualization 
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of metastatic lymph nodes, the sensitivity and specificity were 90% 
and 67% respectively [18]. 
In patients with treated skeletal metastases and a negative 
[99mTc]Tc-PSMA(I&T) scan without lymphogenic and visceral 
secondary lesions, but with a progressive PSA elevation, control 
whole-body bone scintigraphy or follow-up by other standard visual 
methods is recommended. It would be appropriate to discuss the 
possibility of treatment with Xofigo in these patients [19].
Another clinical application of [99mTc]PSMA SPECT-CT, which 
is not discussed in the present study but is cited in recently published 
scientific articles, is the introduction of this method for selective 
radio-guided surgery of metastatic lymph nodes and/or local recur-
rence in the bed of the prostate. Initial data are very encouraging 
for the future use of a gamma probe for intraoperative detection of 
metastatic foci in the pelvis, previously imaged by SPECT-CT using 
[99mTc]Tc-PSMA(I&T) and [99mTc]Tc-PSMA-ALUG [20, 21].
Figure 8A. M/62yr with prostate cancer, T3bN1M1, G3, Gl = 10 (35 + 5). Radiotherapy (2017), androgen deprivation therapy, osteomodulators. 
PSA = 0.66 ng/mL (07/2019). Whole-body scan and target [99mTc]Tc-PSMA-T4 SPECT-CT imaging showed multiple osteosclerotic bone lesions, 
negative due to prior treatment; B. Bone scan was performed 6 months later due to increased PSA = 29 ng/mL, with a positive result for active 
multiple bone metastases in the thoracic and lumbar vertebrae, bilateral ribs, pelvic bones and synchondrosis, left shoulder. There were no 
evidence of local recurrence, lymphogenic and visceral targets. The patient was planned for Xofigo therapy
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Figure 9A. M/75yr with prostate cancer, pT2cpN0M0, G2, Gl = 7 (4 + 3). Radical prostatectomy, radiotherapy (2015) and androgen deprivation 
therapy. PSA = 0.57 ng/mL (03/2019). Whole-body scan and target [99mTc]Tc-PSMA-T4 SPECT-CT imaging showed local recurrence in the prostate 
bed and enlarged single perirectal lymph node on the left with intensive tracer uptake; B. Gross tumour volume (GTV) and Clinical Tumour Volume 
(CTV) delineation based on the [99mTc]Tc-PSMA-T4 imaging results in radiotherapy planning. Radiation dose distribution in the region of the local 
recurrence and the single enlarge perirectal lymph node on the left in the same patient
A
B
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Figure 10. M/75yr with prostate cancer, pT2cpN0M0, Gl = 7 (4 + 3)г. Radical prostatectomy/2016/ PSA = 0.36 ng/mL (02.2019) Whole-body scan 
and target [99mTc]Tc-PSMA-T4 SPECT-CT imaging showed enlarged single iliac lymph node on the left with intensive tracer uptake. Gross tumour 
volume (GTV) and Clinical Tumour Volume (CTV) delineation based on the [99mTc]Tc-PSMA-T4 imaging results in radiotherapy planning. Radiation 
dose distribution in the region of the single enlarged iliac lymph node on the left in the same patient. The PSA value decreased to 0.05 ng/mL 
(м.10.2019) after radiotherapy
Conclusions
Based on these results and the review of the published litera-
ture, it could be summarized that the new [99mTc]Tc-PSMA-T4 tracer 
was shown to have favourable biodistribution and kinetic behav-
iour. This radiopharmaceutical can be prepared in a short time, 
technically easy to perform radiolabelling and quality control, with 
a significantly lower radiation dose for the patient. A whole-body 
scan with subsequent SPECT-CT imaging is recommended within 
one to three hours after intravenous administration. 
The use of [99mTc]Tc-PSMA-T4is a very good alternative as a di-
agnostic method in patients with prostate cancer in nuclear medi-
cine centres that cannot produce [68Ga]Ga-PSMA.
SPECT-CT study with [99mTc]Tc-PSMA-T4 is a promising imaging 
tool showing high sensitivity and specificity with great diagnostic 
potential in patients with recurrent prostate cancer due to intensive 
target uptake in the local relapse of the prostate gland, lymphatic, 
bone and visceral metastases with a high diagnostic accuracy of 
86.11%. These parameters make [99mTc]Tc-PSMA-T4 SPECT-CT 
studies an advanced visual method, cost-effective and widely 
applicable.
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